Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
0.980
-0.002 (-0.22%)
At close: Apr 28, 2026, 4:00 PM EDT
0.980
+0.000 (0.01%)
After-hours: Apr 28, 2026, 4:22 PM EDT
Sunshine Biopharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Sunshine Biopharma stock has a target of 7.00, which predicts an increase of 614.36% from the current stock price of 0.98.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 8, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Sunshine Biopharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Aegis Capital | Aegis Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +614.36% | Oct 8, 2025 |
| Aegis Capital | Aegis Capital | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,430.77% | Dec 5, 2024 |
| Aegis Capital | Aegis Capital | Strong Buy Initiates $5,200 | Strong Buy | Initiates | $5,200 | +530,566.39% | Aug 7, 2023 |
Financial Forecast
Revenue This Year
51.00M
from 36.31M
Increased by 40.47%
Revenue Next Year
n/a
from 51.00M
EPS This Year
-0.33
from -1.44
EPS Next Year
n/a
from -0.33
Revenue Forecast
| Revenue | 2026 |
|---|---|
| High | 52.5M |
| Avg | 51.0M |
| Low | 49.0M |
Revenue Growth
| Revenue Growth | 2026 |
|---|---|
| High | 44.6% |
| Avg | 40.5% |
| Low | 35.0% |
EPS Forecast
| EPS | 2026 |
|---|---|
| High | -0.34 |
| Avg | -0.33 |
| Low | -0.31 |
EPS Growth
| EPS Growth | 2026 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.